Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
2.
J Pers Med ; 13(2)2023 Jan 31.
Artigo em Inglês | MEDLINE | ID: mdl-36836501

RESUMO

The primary treatment for Parkinson's disease (PD) is supplementation of levodopa (L-dopa). With disease progression, people may experience motor and non-motor fluctuations, whereby the PD symptoms return before the next dose of medication. Paradoxically, in order to prevent wearing-off, one must take the next dose while still feeling well, as the upcoming off episodes can be unpredictable. Waiting until feeling wearing-off and then taking the next dose of medication is a sub-optimal strategy, as the medication can take up to an hour to be absorbed. Ultimately, early detection of wearing-off before people are consciously aware would be ideal. Towards this goal, we examined whether or not a wearable sensor recording autonomic nervous system (ANS) activity could be used to predict wearing-off in people on L-dopa. We had PD subjects on L-dopa record a diary of their on/off status over 24 hours while wearing a wearable sensor (E4 wristband®) that recorded ANS dynamics, including electrodermal activity (EDA), heart rate (HR), blood volume pulse (BVP), and skin temperature (TEMP). A joint empirical mode decomposition (EMD) / regression analysis was used to predict wearing-off (WO) time. When we used individually specific models assessed with cross-validation, we obtained > 90% correlation between the original OFF state logged by the patients and the reconstructed signal. However, a pooled model using the same combination of ASR measures across subjects was not statistically significant. This proof-of-principle study suggests that ANS dynamics can be used to assess the on/off phenomenon in people with PD taking L-dopa, but must be individually calibrated. More work is required to determine if individual wearing-off detection can take place before people become consciously aware of it.

3.
Neurol India ; 70(6): 2443-2445, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36537432

RESUMO

Background: Cerebral venous sinus thrombosis (CVST) is a life-threatening condition with a predilection for a younger age group. Patients with CVST can have features of raised intracranial pressure that can be suspected clinically based on ophthalmological findings such as bilateral abduction restriction, papilledema. Case Description: A 27-year-old gentleman presented with 15 days history of headache and seizures with complete abduction restriction of both eyes along with retraction of globe and narrowing of palpebral fissure on abduction. His MRI brain showed superior sagittal sinus thrombosis without any parenchymal lesion. Conclusion: The final diagnosis in our case was bilateral inverse Duane's retraction syndrome with CVST, a co-occurrence that has not been reported in the past and can be missed if the eye movements are attributed to raised intracranial pressure alone.


Assuntos
Síndrome da Retração Ocular , Trombose do Seio Sagital , Trombose dos Seios Intracranianos , Masculino , Humanos , Adulto , Movimentos Oculares , Imageamento por Ressonância Magnética , Neuroimagem
4.
Indian J Med Ethics ; VII(4): 341-342, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35699279

RESUMO

Technology is not only changing the way doctors and patients communicate, but also how physicians interact with other healthcare providers. This interaction has increasingly begun to be over online media such as telemedicine networks/instant messaging apps/social media/emails. The Covid-19 pandemic has further spurred the rapid adoption of these digital healthcare technologies, amplifying the potential risks for data breach of sensitive personal information.


Assuntos
COVID-19 , Telemedicina , Humanos , Pandemias , Atenção à Saúde , Disseminação de Informação
5.
Toxins (Basel) ; 13(5)2021 05 20.
Artigo em Inglês | MEDLINE | ID: mdl-34065541

RESUMO

The visualization of the human body has frequently been groundbreaking in medicine. In the last few years, the use of ultrasound (US) imaging has become a well-established procedure for botulinum toxin therapy in people with cervical dystonia (CD). It is now undisputed among experts that some of the most relevant muscles in this indication can be safely injected under visual US guidance. This review will explore the method from basic technical considerations, current evidence to conceptual developments of the phenomenology of cervical dystonia. We will review the implications of introducing US to our understanding of muscle function and anatomy of common cervical dystonic patterns. We suggest a flow chart for the use of US to achieve a personalized treatment of people with CD. Thus, we hope to contribute a resource that is useful in clinical practice and that stimulates the ongoing development of this valuable technique.


Assuntos
Toxinas Botulínicas/administração & dosagem , Torcicolo/tratamento farmacológico , Ultrassonografia de Intervenção/métodos , Humanos , Fármacos Neuromusculares/administração & dosagem , Medicina de Precisão , Torcicolo/diagnóstico por imagem
7.
Seizure ; 65: 111-117, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30682680

RESUMO

PURPOSE: This randomized control study was conducted to compare the efficacy of sodium valproate (SVP) and levetiracetam (LEV) following initial intravenous lorazepam in elderly patients (age: >60years) with generalized convulsive status epilepticus (GCSE) and to identify predictors of poor seizure control. METHODS: A total of 118 patients (mean age: 67.5 ± 7.5 years, M:F = 1.6:1), who had presented with GCSE were randomized into the SVP or LEV treatment arms. All patients received initial intravenous lorazepam (0.1 mg/kg) followed by one of the two antiepileptic drugs (AEDs), parenteral SVP (20-25 mg/kg) or LEV (20-25 mg/kg). Those who failed to achieve control with the initial AED, were crossed over to receive the other AED. One-hundred patients (SVP = 50; LEV = 50) completed the study. RESULTS: SE could be controlled with lorazepam and one of the AEDs (SVP or LEV) in 71.18% (84/118). Intention-to-treat analysis showed that the two groups did not differ significantly in terms of seizure control [SVP: 41/60 (68.3%); LEV: 43/58 (74.1%), p = 0.486]. Of 100 patients who completed the study, seizure control was achieved in 38/50(76%) in the SVP and 43/50(86%) in the LEV group (p = 0.202). After crossing over to the second AED, SE could be controlled in an additional in 50% (6/12) in SVP (+LEV) group and in 14.3% (1/7) in LEV (+SVP) group. Overall, after the second AED, seizure control was achieved in 77.1% (91/118). Higher STESS was associated with poor therapeutic response (p = 0.049). CONCLUSIONS: The efficacy of SVP and LEV following initial lorazepam in controlling GCSE in elderly population was comparable, hence the choice of AED could be individualized.


Assuntos
Envelhecimento/efeitos dos fármacos , Anticonvulsivantes/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Relação Dose-Resposta a Droga , Eletroencefalografia , Feminino , Humanos , Levetiracetam , Modelos Logísticos , Lorazepam , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Estudos Prospectivos , Método Simples-Cego , Estado Epiléptico/tratamento farmacológico , Resultado do Tratamento , Ácido Valproico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...